In clinical trials, fezolinetant was associated with a transient decrease in luteinizing hormone (LH) levels, but had no significant impact on follicular stimulating hormone (FSH), sex hormone binding globulin (SHBG), estradiol, (free) testosterone, estrone, dehydroepiandriosterone (DHEA) or androstenedione in postmenopausal women
The following information is from a Phase 1 study in 24 premenopausal women:
Data on file.
Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27(4):382-392. https://dx.doi.org/10.1097/GME.0000000000001510.
Fraser GL, Ramael S, Hoveyda HR, Gheyle L, Combalbert J. The NK3 Receptor Antagonist ESN364 Suppresses Sex Hormones in Men and Women. J Clin Endocrinol Metab. 2016;101(2):417-426. https://dx.doi.org/10.1210/jc.2015-3621.
Depypere H, Timmerman D, Donders G, et al. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. J Clin Endocr Metab. 2019;104(12):5893-5905. https://dx.doi.org/10.1210/jc.2019-00677.
The medical information on this website is for educational purposes only and is intended to provide scientific information about Astellas products. This information is not intended as medical advice or clinical recommendations. This website is for use only by United States residents and licensed healthcare professionals (HCPs) practicing in the United States. Product labeling may vary between countries.
Please choose an option that best describes you:
For visitors outside the United States: click here